At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
Vanoxerine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
In Brief
A Phase 2 clinical trial evaluating Vanoxerine and Placebo for Symptomatic Atrial Fibrillation and Atrial Flutter. Completed, enrolled 104 participants across 6 sites in 2 countries.
Detailed Summary
Evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or flutter of recent onset to normal sinus rhythm.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Atrial Fibrillation, Atrial Flutter
CountriesIsrael, Russia
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartNov 2012
Primary CompletionSep 2013
Study CompletionOct 2013
TodayJul 2026
First PostedSep 24, 2012
Enrollment StartNov 1, 2012
Primary CompletionSep 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.8 years ago
Interventions
Vanoxerinedrug
single oral dose
Placebodrug
single oral dose